Clinical Trials
45 trialsBiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
National Cancer Institute (NCI)
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Eastern Cooperative Oncology Group
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population
Mayo Clinic
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NRG Oncology
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Mayo Clinic
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Emory University
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Ohio State University Comprehensive Cancer Center
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
University of California, San Diego
Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen
The First Affiliated Hospital of Xiamen University
Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
University of Utah
SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
Sun Yat-sen University
Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer
Henan Cancer Hospital
Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
Eastern Cooperative Oncology Group
Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin
University of California, San Francisco
Efficacy and Safety of Toripalimab Combined With AP-induced Chemotherapy Followed in Non-metastatic IVB Hypopharyngeal Cancer
Chinese PLA General Hospital
Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer
Fudan University
Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma
Fudan University
Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer
Abramson Cancer Center at Penn Medicine
INSIGHT
Fudan University
Adaptive Radiotherapy for Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer
Sun Yat-sen University
New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma
ChineseAMS
Toripalimab Plus TPF Chemotherapy and Radiotherapy for LA-HPSCC
Peking University
Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer
University of Texas Southwestern Medical Center
Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Toripalimab in Combination With Chemotherapy as Induced Chemotherapy for Localized Hypopharyngeal Cancer
Peking Union Medical College Hospital
Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Samsung Medical Center
Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
Mayo Clinic
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
Dana-Farber Cancer Institute
Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer
Burzynski Research Institute
A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab
University of Zurich
Zinc Supplements in Lowering Cadmium Levels in Smokers
Wake Forest University Health Sciences
Bupropion in Helping Adults Stop Smoking
Roswell Park Cancer Institute
Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer
University of Chicago
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
Fox Chase Cancer Center
TPF-C-HIT
Heidelberg University
Porfimer Sodium in Diagnosing Patients With Head and Neck Cancer
Roswell Park Cancer Institute
Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer
The Second People's Hospital of Sichuan
Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation
Groupe Oncologie Radiotherapie Tete et Cou
Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer
National Cancer Institute (NCI)